[go: up one dir, main page]

Magnussen et al., 1981 - Google Patents

Plasma Accumulation and Metabolism of Orally Administered Single Dose L‐5‐Hydroxytryptophan in Man

Magnussen et al., 1981

Document ID
2812407645413915404
Author
Magnussen I
Jensen T
Rand J
Van Woert M
Publication year
Publication venue
Acta pharmacologica et toxicologica

External Links

Snippet

Single oral doses of L‐5‐hydroxytryptophan (5‐HTP) were administered in combination with L‐aromatic amino acid decarboxylase inhibitors. The time courses of plasma concentrations of 5‐HTP, 5‐hydroxytryptamine (5‐HT) and 5‐hydroxyindoleacetic acid (5‐HIAA) and the …
Continue reading at onlinelibrary.wiley.com (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl group being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application

Similar Documents

Publication Publication Date Title
Kopple et al. Daily requirement for pyridoxine supplements in chronic renal failure
Nissinen et al. Inhibition of catechol-O-methyltransferase activity by two novel disubstituted catechols in the rat
Stacpoole et al. Clinical pharmacology and toxicology of dichloroacetate.
Hu et al. Passive and carrier-mediated intestinal absorption components of captopril
Lykkelund et al. Increased neurotransmitter biosynthesis in phenylketonuria induced by phenylalanine restriction or by supplementation of unrestricted diet with large amounts of tyrosine
Fitzgerald et al. The effects of organic nitrates on prostacyclin biosynthesis and platelet function in humans.
Agrawal et al. Dose proportionality of oral etoricoxib, a highly selective cyclooxygenase‐2 inhibitor, in healthy volunteers
PL193104B1 (en) Novel stable liquid paracetamol-based preparations and method of obtaining them
RU2125448C1 (en) Pharmaceutical composition and a method of its preparing, method of treatment of disorders caused by neurodegenerative processes
Magnussen et al. Plasma Accumulation and Metabolism of Orally Administered Single Dose L‐5‐Hydroxytryptophan in Man
EP2770988B1 (en) New therapy for transthyretin-associated amyloidosis
Raul et al. Beneficial effects of L-arginine on intestinal epithelial restitution after ischemic damage in rats
Wernerman et al. The effect of stress hormones on the interorgan flux of amino acids and on the concentration of free amino acids in skeletal muscle
Frisk‐Holmberg et al. Effect of food on the absorption of vigabatrin.
Arthur et al. Pharmacology of propranolol in patients with cirrhosis and portal hypertension.
Magnussen et al. Bioavailability and related pharmacokinetics in man of orally administered L‐5‐hydroxytryptophan in steady state
Pearlstone et al. Effect of enteral and parenteral nutrition on amino acid levels in cancer patients
Magnussen et al. The effects of aromatic amino acid decarboxylase inhibitors on plasma concentrations of 5‐hydroxytryptophan in man
Lockey et al. Effect of oral activated charcoal on quinine elimination.
Ichinose et al. Increase of catecholamines in mouse brain by systemic administration of γ‐glutamyl l‐3, 4‐dihydroxyphenylalanine
GARFINKEL et al. The effect of a peripheral decarboxylase inhibitor (carbidopa) on monoamine and neuroendocrine function in man
Cadwalladerx et al. Effect of macromolecules on aqueous solubility of cholesterol and hormone drugs
Conlay et al. Tyrosine's pressor effect in hypotensive rats is not mediated by tyramine
Airoldi et al. Effect of pyridoxine on the depletion of tissue pyridoxal phosphate by carbidopa
US20250082577A1 (en) Polymer beadlet compositions and methods of use thereof for improved stability, bioavailability & sustained release